Why the Reiteration?
Monsanto�� earnings in the fiscal third quarter of 2013 were $1.66 per share increasing 1.8% year over year on the back of improved revenues and margins. Revenues for the quarter increased 0.7% year over year to $4.2 billion, driven by an improvement in its global corn business.
Based on the results, management maintained its outlook for fiscal 2013, with earnings in the range of $4.50 - $4.55, indicating year-over-year growth of 20%. This rising business of the company is expected to continue in fiscal 2014 as well, with an expected rise in the corn seed portfolio pricing in fiscal 2014. The improved seed business in the United States also strengthens this belief.
Best Healthcare Technology Stocks To Watch For 2015: EZCORP Inc.(EZPW)
EZCORP, Inc. provides specialty consumer financial services. The company offers pawn loans that are non-recourse loans collateralized by tangible personal property, including jewelry, consumer electronics, tools, sporting goods, and musical instruments, as well as sells merchandise consisting of second-hand collateral forfeited from its pawn lending activities or purchased from customers, and new or refurbished merchandise from third party vendors. It also provides a range of financial services, such as signature loans consisting of payday loans, installment loans, and lines of credit; and auto title loans, which include single payment auto title loans, and auto title lines of credit. In addition, the company offers fee-based credit services to customers seeking loans; and advice and assistance to customers in obtaining loans from unaffiliated lenders, as well as provides debit cards. As of September 30, 2011, it operated a total of 1,111 locations consisting of 433 pawn s tores under the EZPAWN or Value Pawn names, and 436 financial services stores under the EZMONEY name in the United States; 178 pawn stores under the Empe� F�il or Empe� Su Oro names in Mexico; 49 financial services stores under the CASHMAX name in Canada; and 15 financial and retail services stores under the Cash Converters name in Canada. Further, the company operates as a franchisor for 13 franchised Cash Converters stores in Canada. EZCORP, Inc. was founded in 1989 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Ben Levisohn]
Shares of World Acceptance Corporation have plunged 19% to $79.19 at 3:43 p.m.–and dragged down anything remotely connected to payday lending. Cash America International (CSH) has dropped 7.8% to $39.35, pawn-shop operator EZCorp (EZPW) has fallen 3.7% to $12.33, and wire-transfer companies Western Union (WU) and MoneyGram International (MGI) have fallen 2.6% and 5.8%, respectively.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pawn shop operator EZCORP (NASDAQ: EZPW ) has earned a coveted five-star ranking.
Top 10 Rising Stocks To Buy Right Now: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
Top 10 Rising Stocks To Buy Right Now: Caterpillar Inc.(CAT)
Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide. It operates through three lines of businesses: Machinery, Engines, and Financial Products. The Machinery business offers construction, mining, and forestry machinery, including track and wheel tractors, track and wheel loaders, pipelayers, motor graders, wheel tractor-scrapers, track and wheel excavators, backhoe loaders, log skidders, log loaders, off-highway trucks, articulated trucks, paving products, skid steer loaders, underground mining equipment, tunnel boring equipment, and related parts. It also manufactures diesel-electric locomotives; and manufactures and services rail-related products and logistics services for other companies. The Engines business provides diesel, heavy fuel, and natural gas reciprocating engines for Caterpillar machinery, electric power generation systems, marine, petrol eum, construction, industrial, agricultural, and other applications. It offers industrial turbines and turbine-related services for oil and gas, and power generation applications. This business also remanufactures Caterpillar engines, machines, and engine components; and offers remanufacturing services for other companies. The Financial Products business provides retail and wholesale financing alternatives for Caterpillar machinery and engines, solar gas turbines, and other equipment and marine vessels, as well as offers loans and various forms of insurance to customers and dealers. It also offers financing for vehicles, power generation facilities, and marine vessels. The company markets its products directly, as well as through its distribution centers, dealers, and distributors. It was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986. Caterpillar Inc. was founded in 1925 and is headquartered in Peoria, Illinois.
Advisors' Opinion:- [By Dan Dzombak]
Today's Dow leader
Today's Dow leader is Caterpillar (NYSE: CAT ) , up 1.2%. This month the company has taken some heat from short-sellers who panned the company because they believe it will suffer from a slowdown in demand in China. Lending credence to that view was Caterpillar's poor earnings report last week, which showed a 43% drop in income. The stock sold off slightly, finishing down 4% for the week -- the worst performance of any Dow component. In what appears to be an effort to appease shareholders, today Caterpillar announced a $1 billion accelerated share-buyback at market prices. The question investors need to ask themselves is whether Caterpillar is buying at an opportune time or simply trying to appease shareholders in the short run. One Fool contributor believes you shouldn't give up on Caterpillar stock just yet.� - [By Dan Caplinger]
What it means for the Dow
Japan's drop recently has come on the heels of slowing economic growth in China, which remains a lucrative potential market that could help the Japanese economy bolster its own growth. The declines that U.S. investors have seen in Caterpillar (NYSE: CAT ) and Alcoa (NYSE: AA ) lately are just one symptom of the downturn in China, but they demonstrate the challenges that Japanese manufacturing stocks face in taking maximum advantage of the emerging-market opportunity there.
Top 10 Rising Stocks To Buy Right Now: Sigma-Aldrich Corp (SIAL)
Sigma-Aldrich Corporation, incorporated in May 12, 1975, is a life science and high technology company. The Company develops, manufactures, purchases and distributes the range of chemicals, biochemicals and equipment available globally and also provides global biopharmaceutical testing services. These chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. As of December 31, 2012, the Company offered approximately 45,000 equipment products. On January 31, 2012, the Company completed its acquisition of all of interest of BioReliance, a provider of global biopharmaceutical testing services. On April 2, 2012, the Company acquired Research Organics, a supplier of purity biochemicals.
The Company provides products and services that focus on research customers that use smaller quantities of its products in basic life science and high-technology research and development (R&D); manufacturing customers that use its products in quantities in lab-stage development and manufacturing; life science customers who use its biopharmaceutical testing services to facilitate the development, manufacturing and commercialization of biological drugs, and industrial and diagnostic companies that use its products in range of forms of assays and testing, as well as in clinical diagnostics. The Company has a customer base of commercial laboratories, pharmaceutical companies, industrial companies, universities, diagnostics companies, biotechnology companies, electronics companies, hospitals, governmental institutions and non-profit organizations located in the United States and globally.
Advisors' Opinion:- [By Nicole Seghetti]
2. Sigma-Aldrich (NASDAQ: SIAL )
Maker of test tubes and beakers, Sigma-Aldrich has increased its dividend every year since 1976. Even though the company pays a relatively scrawny 1.1% dividend yield, its 21% payout ratio signals the company has ample opportunity to up its dividend for many years to come. - [By ovenerio]
Over the past days hedge funds have been filing their form 13-F, which is a quarterly report of equity holdings by filed institutional investment managers with at least $100 million in equity assets under management, as required by the United States Securities and Exchange Commission (SEC). In this article, let麓s concentrate in one particular hedge fund and try to see the principal holdings in its portfolio. I will look into America First Investment Advisor.Recently the fund reported its equity portfolio, as at the end of June. The total value of the portfolio amounted to $222.9 million, up from $203.2 million disclosed at the end of the previous quarter. Consequently, the fund's total return was 9.7% in the last quarter. The filing revealed that at the end of June, the fund added 14 new positions to its equity portfolio, and sold out of 24 other companies. The top ten portfolio holdings as of the end of the quarter represented 41.8%. The largest changes from previous 13-F麓s fillings are in the tech and energy sectors.In this article, we have selected three companies, in which the fund holds the largest stakes, in terms of market value.The first on the list is The Clorox Company (CLX), in which the fund disclosed a $10.53 million stake with over 115,150 shares. The company is a diversified producer of household cleaning, grocery and specialty food products is also a leading producer of natural personal care products.Long-Term VisionIn October 2013, Clorox introduced its 2020 Strategy. The 2020 Strategy focuses on delivering long-term, profitable growth through the year 2020. The key elements of its strategy to grow sales and earnings over the long term are: category, channel and geographic expansion, increased brand investment, and cost reductions.The company's long-term financial goals include:Growing net sales 3-5 percent annuallyExpanding EBIT margin 25-50 basis points annuallyGenerating free cash flow of 10% to 12% of sales annuallyIt has improved earnings
- [By Luke Jacobi]
Sigma-Aldrich (NASDAQ: SIAL) shares shot up 33.2 percent to $136.40 after Germany's Merck KGaA (OTC: MKGAY) announced its plans to acquire Sigma-Aldrich for $140 per share in cash.
- [By Garrett Cook]
Germany’s Merck KGaA (OTC: MKGAY) announced its plans to acquire Sigma-Aldrich (NASDAQ: SIAL) for $17 billion in cash.
The offer price of $140 per share represents a 37% premium to Sigma-Aldrich’s closing price of $102.37 on September 19.
Top 10 Rising Stocks To Buy Right Now: First Industrial Realty Trust Inc (FR)
First Industrial Realty Trust, Inc. is a real estate investment trust (REIT). The Company is a self-administered and fully integrated real estate company, which owns, manages, acquires, sells, develops and redevelops industrial real estate. It is engaged in the acquisition of individual properties, as well as multi-property portfolios. As of December 31, 2011, its in-service portfolio consisted of 354 light industrial properties, 113 R&D/flex properties, 159 bulk warehouse properties, 105 regional warehouse properties, and eight manufacturing properties containing approximately 68.6 million square feet of gross leasable area (GLA) located in 26 states in the United States and one province in Canada. The Company�� in-service portfolio includes all properties other than developed, redeveloped and acquired properties that have not reached stabilized occupancy (generally defined as properties that are 90% leased).
As of December 31, 2011, it also owned noncontrolling equity interests in, and provided various services to, two joint ventures. The Company�� interests in its properties and land parcels are held through partnerships, corporations, and limited liability companies controlled, directly or indirectly, by the Company, including the Operating Partnership, of which it is the sole general partner with an approximate 94.3% interests as of December 31, 2011. During the year ended December 31, 2011, the Company acquired one industrial property consisting of approximately 0.7 million square feet of GLA in connection with the purchase of the 85% interest in one property. The Company generates revenue primarily from rental income and tenant recoveries from long-term (generally three to six years) operating leases of its industrial properties. It also generates income from the sale of its properties.
As of December 31, 2011, the Non-Strategic Assets consisted of 133 industrial properties, including approximately 11.3 million square feet of GLA, and land parcels of approximatel! y 359 gross acres. As of December 31, 2011, the Company owned 739 in-service industrial properties containing approximately 66.3 million square feet of GLA. During 2011, the Company owned 739 in-service industrial properties containing an aggregate of approximately 66.3 million square feet of GLA in 26 states of the United States, and one province in Canada, with a diverse base of approximately 1,900 tenants engaged in a variety of businesses, including manufacturing, retail, wholesale. During 2011, the Company sold 36 industrial properties totaling approximately 2.9 million square feet of GLA and one land parcel.
Advisors' Opinion:- [By Rich Duprey]
Industrial real estate owner�First Industrial� (NYSE: FR ) �announced yesterday�its second-quarter dividend of $0.085 per share/unit, the same rate it paid last quarter when it reinstated its dividend after a four-year hiatus.
Top 10 Rising Stocks To Buy Right Now: Etfs Gold Trust (SGOL)
ETFS Gold Trust (the Trust) is an investment trust. The investment objective of the Trust is for the Shares to reflect the performance of the price of gold bullion, less the expenses of the Trust�� operations. The Trust holds gold bullion and issues ETFS Physical Swiss Gold Shares (the Shares) in exchange for deposits of gold and distributes gold in connection with redemption of Baskets. The sponsor of the Trust is ETF Securities USA LLC (the Sponsor). The trustee of the Trust is The Bank of New York Mellon and the custodian is JP Morgan Chase Bank N.A. Advisors' Opinion:- [By Peter Pham]
Although the Fed doubled its bond buying last September, the top gold exchange-traded funds, or ETFs, including SPDR Gold Shares (NYSEMKT: GLD ) , iShares Gold Trust (NYSEMKT: IAU ) , and ETFS Physical Swiss Gold Shares (NYSEMKT: SGOL ) , have dropped around 25% each over the last 12 months, which speaks to gold's extreme vulnerability to QE tapering. Even the mere mention of tapering seems to send gold into a tailspin, as seen with SPDR Gold Shares, which has plunged 24% year to date and also suffered massive losses with its physical holdings. Market Vectors Gold Miners ETF (NYSEMKT: GDX ) has suffered a massive drop of 48% so far in 2013, making it one of the worst-performing ETFs this year.
Top 10 Rising Stocks To Buy Right Now: Peoples Bancorp of North Carolina Inc.(PEBK)
Peoples Bancorp of North Carolina, Inc. operates as the holding company for Peoples Bank, which provides various banking products and services to individuals and small to medium-sized businesses in Catawba Valley and surrounding communities in North Carolina. Its deposit products include demand deposits; interest-bearing checking accounts; NOW, MMDA, and savings deposits; regular savings accounts; money market accounts; time deposits; and certificates of deposit. The company?s lending portfolio comprises commercial loans, real estate mortgage loans, real estate construction loans, and consumer loans, as well as agricultural loans. It also provides real estate appraisal and real estate brokerage services, as well as access to investment counseling and non-deposit investment products, such as stocks, bonds, mutual funds, tax deferred annuities, and related brokerage services. It operates 22 banking offices located in Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Cla remont, Hiddenite, Hickory, Charlotte, Monroe, Cornelius, Mooresville, and Raleigh in North Carolina, as well as a loan production office in Denver, North Carolina. The company was founded in 1912 and is based in Newton, North Carolina.
Advisors' Opinion:- [By Tim Melvin]
Stilwell�� funds also bought more shares of Peoples Bancorp of North Carolina (PEBK). The bank operates in central North Carolina and has 22 branches with a little over $1 billion in assets. PEBK just reported a solid quarter, increasing earnings by more than 40% year-over-year while working down nonperforming assets by 30%. The bank also grew its deposit base in the quarter — a difficult accomplishment for many small banks this year.
No comments:
Post a Comment